DUBLIN--(BUSINESS WIRE)--The "Crigler-Najjar Syndrome - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Crigler-Najjar Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Crigler-Najjar Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Crigler-Najjar Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Crigler-Najjar Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed and Preclinical stages are 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Key Topics Covered:
- Crigler-Najjar Syndrome - Overview
- Crigler-Najjar Syndrome - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Crigler-Najjar Syndrome - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Crigler-Najjar Syndrome - Companies Involved in Therapeutics Development
- Audentes Therapeutics Inc
- Genethon SA
- International Stem Cell Corp
- Promethera Biosciences SA
For more information about this report visit https://www.researchandmarkets.com/research/zn65ng/criglernajjar